Bicycle Therapeutics to Present Radiopharmaceuticals Data at European Association of Nuclear Medicine 2024 Congress

BCYC 10.16.2024

Full Press ReleaseSEC FilingsOur BCYC Tweets

About Gravity Analytica

Recent News

  • 01.15.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones
  • 01.09.2025 - Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.13.2025 - 8-K Current report
  • 01.06.2025 - 4 Statement of changes in beneficial ownership of securities

Company to host conference call and webcast onWednesday, Oct. 23, at8 a.m. ETto review the data and outline radiopharmaceuticals strategy

CAMBRIDGE, England&BOSTON--(BUSINESS WIRE)--Oct. 16, 2024--Bicycle Therapeutics plc(NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the company will present data highlighting its potential to develop differentiated radiopharmaceutical molecules, called Bicycle Radionuclide Conjugates (BRC®), at theEuropean Association of Nuclear Medicine(EANM) 2024Congresstaking placeOctober 19-23inHamburg, Germany.

The German Cancer Consortium(DKTK), part of a cooperative network with theGerman Cancer Research Center(DKFZ), will present the first human imaging data for a BRC targeting MT1-MMP, a tumor antigen overexpressed in many cancers, during an oral presentation. In an online-only poster (e-poster), the company will present information about BRCs for radioisotope delivery to solid tumors. Additionally,Bicycle Therapeuticswill host a conference call and webcast for analysts and investors onWednesday, Oct. 23, at8 a.m. ETto review the data and outline the company’s radiopharmaceuticals strategy.

Oral Presentation by DKTK:Title:Preclinical characterization of a phage display derived MT1-MMP-specific bicyclic peptide for radiotheranostic applicationsSession Number:1504Session Title:M2M Track - TROP Session: Radiopharmaceutical Sciences +Translational Molecular Imaging & Therapy Committee: Targeted Radionuclide TherapyDate and Time:Tuesday, Oct. 22, at3:50-4 p.m. CESTPresentation Number:OP-673Presenter:Ann-Christin Eder, Ph.D.,University Medical Center Freiburg

E-Poster byBicycle Therapeutics:Title:Bicycle Radionuclide Conjugates for radioisotope delivery to solid tumorsSession Number:EP-03Session Title:Preclinical Studies -> A1 Medical Preclinical -> A13 Preclinical Oncologye-Poster Number:EP-0032Lead Author:Gemma Mudd, Ph.D.,Bicycle Therapeutics

Conference Call and Webcast Information

Bicycle Therapeuticswill host a conference call and webcast onWednesday, Oct. 23, at8 a.m. ETto review the first human imaging data and outline the company’s radiopharmaceuticals strategy. To access the call, please dial +1-833-816-1408 (U.S.) or +1-412-317-0501 (international) and ask to join theBicycle Therapeuticscall. A live webcast and replay of the conference call will be available in the Investor section of the company’s website,www.bicycletherapeutics.com.

AboutBicycle Therapeutics

Bicycle Therapeuticsis a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle®molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin (formerly BT8009), a Bicycle®Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist®(Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle Radionuclide Conjugates (BRC®) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle®technology to develop therapies for diseases beyond oncology.

Bicycle Therapeuticsis headquartered inCambridge, UK, with many key functions and members of its leadership team located inCambridge, Mass.For more information, visitbicycletherapeutics.com.

Forward Looking Statements

This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding the potential to develop differentiated radiopharmaceutical molecules using Bicycle’s platform, and Bicycle’s anticipated progress across its R&D pipeline and the advancement of its product candidates. Bicycle may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in research and development and in the initiation, progress and completion of clinical trials and clinical development of Bicycle’s product candidates; the risk that Bicycle may not realize the intended benefits of its technology or partnerships; timing of results from clinical trials; whether the outcomes of preclinical studies will be predictive of clinical trial results; the risk that trials may have unsatisfactory outcomes; potential adverse effects arising from the testing or use of Bicycle’s product candidates; and other important factors, any of which could cause Bicycle’s actual results to differ from those contained in the forward-looking statements, are described in greater detail in the section entitled “Risk Factors” in Bicycle’s Quarterly Report on Form 10-Q filed with theSecurities and Exchange Commission(SEC) onAugust 6, 2024, as well as in other filings Bicycle may make with theSECin the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Bicycle expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241016119406/en/

Investors:Stephanie YaoSVP, Investor Relations and Corporate Communicationsstephanie.yao@bicycletx.com857-523-8544

Matthew DeYoungArgot Partnersir@bicycletx.com212-600-1902

Media:Jim O’ConnellWeber Shandwickmedia@bicycletx.com312-988-2343

Source:Bicycle Therapeutics plc

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com